Prescribing information

 

Preview resources for healthcare providers about Xolair.

As part of our mission to be as environmentally friendly as possible, we provide our resources in electronic form.

These materials should not be printed by healthcare professionals.

Resources for healthcare professionals

 

SELF-ADMINISTRATION GUIDE

Guidance document to help HCPs train their patients with Chronic Spontaneous Urticaria (CSU) to self-administer Xolair treatment. Please contact a Novartis representative to order this material.

View

 

Image

SELF-ADMINISTRATION INITIATION CHECKLIST

A checklist for HCPs when guiding their patients with CSU on self-administration of Xolair. Please contact a Novartis representative to order this material.

View

 

Image of the Prescriber's checklist

SELF-ADMINISTRATION COMPETENCY AND IMPLEMENTATION CHECKLIST

A checklist for HCPs to ascertain their patient/carer's proficiency in administering Xolair treatment. Please contact a Novartis representative to order this material.

View

 

Image of the Prescriber's checklist

SELF-ADMINISTRATION DISCUSSION GUIDE

This flipchart is to help facilitate discussions between HCPs and patients with CSU being treated with Xolair. Please contact a Novartis representative to order this material.

View

 

Resources for healthcare professionals designed to support their patients prescribed Xolair

MYTHERAPY APP

A private module of the MyTherapy app for patients prescribed Xolair for CSU where patients can track injections, symptoms and access useful information.

The MyTherapy app is run by SmartPatient, and Novartis has paid for this private module specifically for patients prescribed Xolair for CSU.

View

 

INJECTION VIDEOS

Two videos showing the injection procedure for patients and carers.

Patient
View

Carer
View

 

PATIENT SELF-ADMINISTRATION STARTER KIT

This patient kit contains: 4x A6 booklets, 1x medical emergency card, 1x magnetic dosing card and 1x MyTherapy app flyer. Please contact a Novartis representative to order this material.

View

 

*A post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.1
Patients with no known history of anaphylaxis may self-inject Xolair or be injected by a caregiver from the 4th dose onwards if a physician determines that this is appropriate. The patient or the caregiver must have been trained in the correct injection technique and the recognition of the early signs and symptoms of serious allergic reactions.

Indication: Xolair is indicated as add-on therapy for the treatment of Chronic Spontaneous Urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment..2

CSU, Chronic Spontaneous Urticaria: DLQI, Dermatology Life Quality Index.

Reference

  1. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.<
  2. Xolair® (omalizumab) Summary of Product Characteristics.
XSU20-C024(1) November 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]